Related Experiment Video
Updated: Jul 17, 2026
08:43
Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice
Published on: January 31, 2020
6.7K
A Case of Orofacial Granulomatosis Treated With Intravenous Rituximab
Sonia Selvaraj1, Anuradha Priyadarshini1, Krishnakanth Muralidhar1
1Dermatology, Sri Ramachandra Institute of Higher Education and Research, Chennai, IND.
Cureus
|April 7, 2025
Summary
Orofacial granulomatosis (OFG) is a condition causing oral swelling. Rituximab showed promise in reducing OFG symptoms when standard treatments were ineffective.
Area of Science:
- Oral medicine
- Dermatology
- Immunology
Background:
- Orofacial granulomatosis (OFG) is characterized by granuloma formation in oral and perioral tissues.
- OFG presents diagnostic and therapeutic challenges, often requiring multidisciplinary management.
Observation:
- A 32-year-old female presented with a year of asymptomatic lower lip, buccal mucosa, and lower face swelling, plus dysphagia.
- Biopsy confirmed OFG, and the patient showed poor response to prednisolone, azathioprine, and hydroxychloroquine (HCQ).
Findings:
- Treatment with three doses of rituximab resulted in a 50% reduction in swelling after six months.
- This suggests rituximab is a viable option for refractory OFG.
Implications:
- Rituximab offers a potential therapeutic avenue for OFG cases unresponsive to conventional therapies.
- Further investigation into biologic agents for OFG management is recommended to improve patient outcomes.
